Global Information
회사소개 | 문의 | 비교리스트

말단비대증 및 거인증 : 역학 예측(-2029년)

Acromegaly and Gigantism - Epidemiology Forecast to 2029

리서치사 GlobalData
발행일 2020년 11월 상품코드 971333
페이지 정보 영문 49 Pages 배송안내
가격
US $ 3,995 ₩ 5,775,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,990 ₩ 11,551,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 11,985 ₩ 17,327,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


말단비대증 및 거인증 : 역학 예측(-2029년) Acromegaly and Gigantism - Epidemiology Forecast to 2029
발행일 : 2020년 11월 페이지 정보 : 영문 49 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

2019년 현재 세계 주요 7개국의 말단비대증 진단 유병자수(15세 이상)는 43,220명을 기록했습니다. 국가별로 보면 미국이 26,549명으로 가장 많고, 스페인이 1,775명으로 최소가 되고 있습니다.

세계 주요 7개국(미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 캐나다)의 말단비대증 및 거인증 발증 상황과 향후 전망에 대해 분석했으며, 질환 특징과 현재 유병자 발증 상황, 향후 10년간 유병건수 동향 전망, 성별·연령별·병존증 종류별 등의 상세 동향 등을 조사했습니다.

목차

제1장 목차

제2장 말단비대증 및 거인증 : 주요 요약

제3장 역학

  • 질환 배경
  • 위험인자와 병존증
  • 세계의 과거 동향
  • 예측 방법
    • 정보 출처
    • 예측 가정과 방법
    • 말단비대증 및 거인증 진단 유병자수
    • 말단비대증 및 거인증 진단 유병자수 : 거대선종을 병발한 경우
    • 말단비대증 및 거인증 진단 유병자수 : 당뇨병을 병발한 경우
    • 말단비대증 및 거인증 진단 유병자수 : 심혈관질환을 병발한 경우
    • 말단비대증 및 거인증 진단 유병자수 : 고혈압을 병발한 경우
  • 말단비대증 역학 예측(2019-2029년)
    • 말단비대증 진단 유병자수
    • 말단비대증 진단 유병자수 : 성별
    • 말단비대증 진단 유병자수 : 연령별
    • 말단비대증 진단 유병자수 : 거대선종을 병발한 경우
    • 말단비대증 진단 유병자수 : 각종 병존증을 병발한 경우
    • 거인증 진단 유병자수
    • 거인증 진단 유병자수 : 성별
    • 거인증 진단 유병자수 : 연령별
    • 거인증 진단 유병자수 : 거대선종을 병발한 경우
    • 거인증 진단 유병자수 : 각종 병존증을 병발한 경우
  • 토론
    • 역학 예측에 의한 인사이트
    • 분석의 한계
    • 분석의 강점

제4장 부록

KSM 20.12.04

List of Tables

List of Tables

  • Table 1: Summary of Newly Added Data Types and Countries
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbidities for Acromegaly and Gigantism
  • Table 4: Global Consensus Criteria for the Diagnosis and Cure of Acromegaly

List of Figures

List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of Acromegaly (N), Both Sexes, Ages ≥15 Years, 2019 and 2029
  • Figure 2: 7MM, Diagnosed Prevalent Cases of Gigantism (N), Both Sexes, All Ages, 2019 and 2029
  • Figure 3: 7MM, Diagnosed Prevalence of Acromegaly (%), Men and Women, Ages ≥15 Years, 2019
  • Figure 4: 7MM, Diagnosed Prevalence of Gigantism (%), Men and Women, All Ages, 2019
  • Figure 5: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of Acromegaly
  • Figure 6: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Gigantism
  • Figure 7: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Acromegaly and Gigantism with Macroadenoma
  • Figure 8: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Acromegaly and Gigantism with Diabetes
  • Figure 9: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Acromegaly and Gigantism with Cardiovascular Disease
  • Figure 10: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Acromegaly and Gigantism with Hypertension
  • Figure 11: 7MM, Diagnosed Prevalent Cases of Acromegaly, Both Sexes, Ages ≥15 Years, N, 2019
  • Figure 12: 7MM, Diagnosed Prevalent Cases of Acromegaly by Sex, Ages ≥15 Years, N, 2019
  • Figure 13: 7MM, Diagnosed Prevalent Cases of Acromegaly by Age, Both Sexes, N, 2019
  • Figure 14: 7MM, Diagnosed Prevalent Cases of Acromegaly with Macroadenoma, Both Sexes, Ages ≥15 Years, N, 2019
  • Figure 15: 7MM, Diagnosed Prevalent Cases of Acromegaly with Comorbidities, Both Sexes, Ages ≥15 Years, N, 2019
  • Figure 16: 7MM, Diagnosed Prevalent Cases of Gigantism, Both Sexes, All Ages, N, 2019
  • Figure 17: 7MM, Diagnosed Prevalent Cases of Gigantism, by Sex, All Ages, N, 2019
  • Figure 18: 7MM, Diagnosed Prevalent Cases of Gigantism by Age, Both Sexes, N, 2019
  • Figure 19: 7MM, Diagnosed Prevalent Cases of Gigantism with Macroadenoma, Both Sexes, All Ages, N, 2019
  • Figure 20: 7MM, Diagnosed Prevalent Cases of Gigantism with Comorbidities, Both Sexes, All Ages, N, 2019

Acromegaly and gigantism are rare disorders of the pituitary gland, characterized by the hypersecretion of growth hormone (GH). In 98% of the cases of acromegaly and gigantism, the hypersecretion of GH results from a benign GH- secreting pituitary adenoma (Sesmilo, 2013). A common sign of acromegaly is enlarged hands and feet, and the disease can also cause gradual changes in the shape of the face, such as a protruding lower jaw and brow, an enlarged nose, thickened lips, and wider spacing between the teeth. Progression of acromegaly can result in major health problems such as diabetes mellitus, cardiovascular disease, hypertension, sleep apnea, carpal tunnel syndrome, and spinal cord compression (Mayo Clinic, 2019). While both acromegaly and gigantism are complications of uncontrolled GH levels, the presentations of the two hormonal diseases are very different; most notably, acromegaly occurs in adulthood and gigantism occurs during childhood (Eugster and Pescovitz, 1999). In 2019, the 7MM combined had 43,220 diagnosed prevalent cases of acromegaly in both sexes for ages 15 years and older.

The US accounted for the majority of these cases with 26,549 diagnosed prevalent cases, while Spain accounted for the fewest cases with 1,775 cases in 2019. GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of acromegaly to 47,340 cases in 2029 in the 7MM at an Annual Growth Rate (AGR) of 0.95% during the forecast period. In 2019, the 7MM combined had 643 diagnosed prevalent cases of gigantism in both sexes for all ages. GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of gigantism to 675 cases in 2029 in the 7MM at an AGR of 0.50% during the forecast period. Any change in the diagnosed prevalent cases of acromegaly and gigantism in the 7MM is attributable to changing population demographics and changing diagnosed prevalence rates in the respective markets.

Scope

  • The Acromegaly and Gigantism Report provides an overview of the risk factors, comorbidities, and the global and historical trends for acromegaly and gigantism in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Canada).
  • The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of acromegaly and gigantism segmented by sex and age (ages 15 years and above in acromegaly cases, and all ages in gigantism cases). Additionally, GlobalData epidemiologists estimated the cases of type of pituitary adenoma (macroadenoma) and comorbidities (cardiovascular disease, diabetes, and hypertension) among the diagnosed prevalent cases of acromegaly and gigantism in the 7MM.
  • The acromegaly and gigantism epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

  • The Acromegaly and Gigantism Epidemiology series will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the global acromegaly and gigantism market.
  • Quantify patient populations in the global acromegaly and gigantism market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for acromegaly and gigantism therapeutics in each of the markets covered.
  • Understand magnitude of type of pituitary adenoma and comorbidities of acromegaly and gigantism.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Acromegaly and Gigantism: Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
    • 3.4.3 Diagnosed Prevalent Cases of Acromegaly and Gigantism
    • 3.4.4 Diagnosed Prevalent Cases of Acromegaly and Gigantism with Macroadenoma
    • 3.4.5 Diagnosed Prevalent Cases of Acromegaly and Gigantism with Diabetes
    • 3.4.6 Diagnosed Prevalent Cases of Acromegaly and Gigantism with Cardiovascular Disease
    • 3.4.7 Diagnosed Prevalent Cases of Acromegaly and Gigantism with Hypertension
  • 3.5 Epidemiological Forecast for Acromegaly, 2019-2029
    • 3.5.1 Diagnosed Prevalent Cases of Acromegaly
    • 3.5.2 Sex-Specific Diagnosed Prevalent Cases of Acromegaly
    • 3.5.3 Age-Specific Diagnosed Prevalent Cases of Acromegaly
    • 3.5.4 Diagnosed Prevalent Cases of Acromegaly with Macroadenoma
    • 3.5.5 Diagnosed Prevalent Cases of Acromegaly with Comorbidities
    • 3.5.6 Diagnosed Prevalent Cases of Gigantism
    • 3.5.7 Sex-Specific Diagnosed Prevalent Cases of Gigantism
    • 3.5.8 Age-Specific Diagnosed Prevalent Cases of Gigantism
    • 3.5.9 Diagnosed Prevalent Cases of Gigantism with Macroadenoma
    • 3.5.10 Diagnosed Prevalent Cases of Gigantism with Comorbidities
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of the Analysis
    • 3.6.3 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer
Back to Top
전화 문의
F A Q